Somapacitan is under investigation in clinical trial NCT01706783 (A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults with Growth Hormone Deficiency).
Chengdu Pukang has a professional R&D team with rich experience, and innovative ideas, which can meet the various needs of customers from custom synthesis to mass production.
English
